Skip to main content

Omeros reports growing Omidria sales after deal with British eye care company

Seattle-based Omeros sold its Omidria drug franchise to Rayner Surgical Group in December in a deal projected to be worth more than $1 billion.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.